Chronic, recurrent Lymphocytic Leukemia Completed Phase 2 Trials for Cladribine (DB00242)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00764517Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaTreatment